Newsroom

latest news from ose
and across our portfolio

Featured News

DJS Antibodies to be acquired by AbbVie
DJS Antibodies to be acquired by AbbVie
MiroBio
MiroBio to be acquired by Gilead Sciences for approximately $405 million
Oxford Science Enterprises raises £250 million
Oxford Science Enterprises raises £250 millionArticle links to firstlightfusion.com
First Light Fusion
First Light Fusion achieves world first fusion result, proving unique new target technologyArticle links to www.omass.com
OMass Therapeutics
OMass Therapeutics raises $100 million in Series B financing to progress drug pipeline in immunology and rare diseasesArticle links to www.oslerdiagnostics.com
Osler Diagnostics raises $85 million in Series C financing
Osler Diagnostics raises $85 million in Series C financingArticle links to quantummotion.tech
Quantum Motion industry milestone brings mass production of quantum chips closer
Quantum Motion industry milestone brings mass production of quantum chips closer
BehaVR
OxfordVR to combine with BehaVR to confront the mental health crisis with the largest VR delivery platform for evidence-based digital therapeutics

All News

Portfolio NewsGrey Wolf TherapeuticsGrey Wolf Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GRWD5769 in Patients with Advanced Solid TumoursPortfolio NewsGrey Wolf TherapeuticsGrey Wolf Therapeutics closes oversubscribed $49 million Series B financing to advance first-of-its-kind neoantigen creation approaches